Work

Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

Year: 2014

Type: article

Abstract: We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.04035-14

Authors: Dong Sik Jung, Frank P. Tverdek, Dimitrios P. Kontoyiannis

Institutions: The University of Texas MD Anderson Cancer Center, Dong-A University

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, Gilead Sciences